Who makes HPV16 Ct-DNA dosing?

HPV16 Ct-DNA dosing is developed by UNICANCER.

What development phase is HPV16 Ct-DNA dosing in?

HPV16 Ct-DNA dosing is in Phase 2.

Last reviewed 2026-04-19 · How we verify

HPV16 Ct-DNA dosing

UNICANCER · Phase 2 active Biologic

At a glance

Generic name	HPV16 Ct-DNA dosing
Sponsor	UNICANCER
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

HPV16 Ct-DNA dosing CI brief — competitive landscape report
HPV16 Ct-DNA dosing updates RSS · CI watch RSS
UNICANCER portfolio CI